Protara Therapeutics (TARA) News Today $5.39 +0.21 (+4.05%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Protara Therapeutics: Rising From The AshesDecember 14, 2024 | seekingalpha.comProtara Therapeutics Raises $100M in Stock OfferingDecember 11, 2024 | markets.businessinsider.comProtara Announces Closing of $100 Million Public OfferingDecember 11, 2024 | globenewswire.comProtara Therapeutics announces common stock offering, no amount givenDecember 11, 2024 | markets.businessinsider.comProtara Therapeutics 13.69M share Spot Secondary priced at $6.25December 10, 2024 | markets.businessinsider.comProtara Therapeutics: Carving New Roads In Bladder CancerDecember 10, 2024 | seekingalpha.comProtara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 CatalystDecember 10, 2024 | seekingalpha.comProtara Prices Public Offering Of 13.69 Mln Shares At $6.25/Shr, To Raise $100 MlnDecember 10, 2024 | markets.businessinsider.comProtara Announces Pricing of $100 Million Public OfferingDecember 9, 2024 | globenewswire.comProtara Announces Proposed Public OfferingDecember 9, 2024 | globenewswire.comInstitutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the mostDecember 7, 2024 | finance.yahoo.comProtara Therapeutics (NASDAQ:TARA) Given "Buy" Rating at GuggenheimGuggenheim restated a "buy" rating and set a $20.00 price target on shares of Protara Therapeutics in a report on Friday.December 6, 2024 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Friday.December 6, 2024 | marketbeat.comProtara Therapeutics Reports Promising Phase 2 Trial ResultsDecember 6, 2024 | markets.businessinsider.comProtara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz SpikesDecember 5, 2024 | msn.comWall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than ExpectedDecember 5, 2024 | msn.comProtara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment TrialsDecember 5, 2024 | marketwatch.comProtara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCDecember 5, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for TARA FY2024 Earnings?Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 earnings per share estimates for Protara Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will earnNovember 18, 2024 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short InterestProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,740,000 shares, an increase of 18.1% from the October 15th total of 2,320,000 shares. Based on an average trading volume of 179,100 shares, the days-to-cover ratio is currently 15.3 days.November 16, 2024 | marketbeat.comProtara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic OncologyNovember 15, 2024 | globenewswire.comProtara Therapeutics (NASDAQ:TARA) Stock, Option ChainNovember 14, 2024 | benzinga.comHC Wainwright Reaffirms "Buy" Rating for Protara Therapeutics (NASDAQ:TARA)HC Wainwright restated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday.November 14, 2024 | marketbeat.comProtara Therapeutics Reports Increased R&D ExpensesNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)November 13, 2024 | markets.businessinsider.comProtara Therapeutics sees cash runway into 2026November 13, 2024 | markets.businessinsider.comProtara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 13, 2024 | markets.businessinsider.comProtara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comProtara Therapeutics Announces Fast Track Designation For Intravenous Choline ChlorideOctober 21, 2024 | markets.businessinsider.comProtara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral SupportOctober 21, 2024 | globenewswire.comProtara Therapeutics (NASDAQ:TARA) Stock, Insider Trading ActivityOctober 7, 2024 | benzinga.comProtara Therapeutics (NASDAQ:TARA) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 32,600 Shares of StockSeptember 13, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)September 12, 2024 | markets.businessinsider.comOpaleye Management Inc. Reduces Stake in Protara Therapeutics Inc.September 12, 2024 | finance.yahoo.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 36,492 Shares of StockSeptember 11, 2024 | insidertrades.comProtara Reports Study Results On Choline Deficiency, Liver Injury In Patients On Parenteral SupportSeptember 10, 2024 | markets.businessinsider.comProtara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsSeptember 9, 2024 | globenewswire.comProtara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportSeptember 9, 2024 | globenewswire.comProtara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comProtara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 6, 2024 | finance.yahoo.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $27,806.24 in StockJuly 19, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 8,497 Shares of StockJuly 12, 2024 | insidertrades.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $17,570.56 in StockJuly 4, 2024 | insidertrades.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 46,574 SharesJune 29, 2024 | insidertrades.comOpaleye Management Inc. Sells 12,725 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) StockJune 29, 2024 | insidertrades.comProtara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 24, 2024 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 9,230 SharesJune 1, 2024 | insidertrades.comProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest UpdateProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,360,000 shares, a growth of 32.0% from the April 30th total of 1,030,000 shares. Based on an average daily volume of 381,100 shares, the days-to-cover ratio is currently 3.6 days.May 31, 2024 | marketbeat.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 33,000 Shares of StockMay 24, 2024 | insidertrades.com Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol TARA Media Mentions By Week TARA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼-0.120.60▲Average Medical News Sentiment TARA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼11▲TARA Articles Average Week Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARCT News ZVRA News KOD News CRVS News VERV News YMAB News SIGA News KRRO News AURA News KALV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
